A Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated by the Body and How the Body Absorbs, Distributes, Metabolizes and Excretes ZL-1310

2024-514446-36-00 Protocol ZL-1310-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 21 Nov 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 11 sites · Protocol ZL-1310-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 169
Countries 1
Sites 11

Small Cell Lung Cancer

Key facts

Sponsor
Zai Lab (US) LLC
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
21 Nov 2024 → ongoing
Decision date (initial)
2024-10-31
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Small Cell Lung Cancer

VersionLevelCodeTermSystem organ class
21.1 PT 10041067 Small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Zai Lab (US) LLC

Sponsor organisation
Zai Lab (US) LLC
Address
314 Main Street Ste 04-100
City
Cambridge
Postcode
02142-1042
Country
United States

Scientific contact point

Organisation
Zai Lab (Shanghai) Co. Ltd.
Contact name
Yinjia Fu

Public contact point

Organisation
Zai Lab (Shanghai) Co. Ltd.
Contact name
Yinjia Fu

Locations

1 EU/EEA country · 11 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 80 11
Rest of world
United States, China
89

Investigational sites

Spain

11 sites · Ongoing, recruiting
Vall D Hebron Institute Of Oncology
Oncology Department, Calle Natzaret 115, 08035, Barcelona
Hospital Universitario Ramon Y Cajal
Oncology Department, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
University Hospital Virgen Del Rocio S.L.
Oncology Department, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Hm Nou Delfos
Oncology Department, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Universitario Hm Sanchinarro
Oncology Department, Calle Ona 10, 28050, Madrid
Hospital Clinico Universitario De Valencia
Oncology Department, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Y Politecnico La Fe
Oncology Department, Avenida De Fernando Abril Martorell 106, 46026, Valencia
Hospital Universitario Regional De Malaga
Oncology Department, Avenida De Carlos De Haya S/N, 29010, Malaga
Hospital Universitario Quironsalud Madrid
Oncology Department, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Virgen De La Macarena
Oncology Department, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Hospital Universitario 12 De Octubre
Oncology Department, Bloque D, Avenida De Cordoba Sn, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-11-21 2024-11-27

Application history

10 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-31 Spain Acceptable
2024-10-31
2024-10-31
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-11 Spain Acceptable
2024-10-31
2025-02-11
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-04-02 Spain Acceptable
2024-10-31
2025-04-02
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-04-16 Spain Acceptable
2024-10-31
2025-04-16
5 SUBSTANTIAL MODIFICATION SM-1 2025-04-29 Spain Acceptable
2025-06-25
2025-06-25
6 NON SUBSTANTIAL MODIFICATION NSM-4 2025-07-07 Spain Acceptable
2025-06-25
2025-07-07
7 SUBSTANTIAL MODIFICATION SM-2 2025-08-08 Spain Acceptable
2025-08-11
2025-08-11
8 SUBSTANTIAL MODIFICATION SM-3 2025-10-10 Spain Acceptable
2025-12-26
2026-01-09
9 SUBSTANTIAL MODIFICATION SM-4 2026-02-19 Spain Acceptable
2026-04-06
2026-04-13
10 NON SUBSTANTIAL MODIFICATION NSM-5 2026-04-27 Spain Acceptable
2026-04-06
2026-04-27